NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrintยฎ Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ August 12, 2025 โ Agendia, Inc., a leader in innovative genomic testing for breast cancer, today announced the publication of new findings in JNCI Cancer Spectrum validating Read More
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrintยฎ and BluePrintยฎ in Diverse Patient Populations Across Breast Cancer Subtypesย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ May 27, 2025 โ Agendiaยฎ, Inc., a leader in precision Read More
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCOยฎ Annual Meeting
FLEX Study reaches milestone of 20,000 enrolled patients, providing new insights on genomic testing across diverse patient populations IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ May 15, 2025 โ Agendiaยฎ, Inc., announced today that Read More
Agendia to Present FLEX Study Data on Impact of BluePrint at ESMO Breast Cancer 2025
Real-world analysis shows BluePrintยฎ identifies chemotherapy-sensitive Basal-type tumorsย among MammaPrintยฎ High Risk HR+ HER2- breast cancers, supporting more personalizedย treatment strategies.ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ May 6, 2025 โ Agendiaยฎ, Inc., Read More
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting
Poster presentation to highlight new data on MammaPrintยฎ and BluePrintยฎ utility for informing axillary surgery decisions in the neoadjuvant setting. Agendia to present at Breast Fellows University Annual Meeting and host Educational Dinner Symposium Read More
MammaPrintยฎ Reimbursement Indication Extended in Belgium
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ February 11, 2025 โ Agendiaยฎ, Inc. announced today that the National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement indication for Read More
Agendia Provides Review of Successful 2024 Advancing the Field of Breast Cancer Treatment
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Businessย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ January 9, 2025 โ Agendiaยฎ, Inc. today ย provided a topline review of the companyโs key Read More